Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
07:00am, Thursday, 30'th Jul 2026
– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –�
Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline
11:06am, Wednesday, 29'th Jul 2026
EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Thursday, 16'th Jul 2026
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
EyePoint Appoints Tarek S. Hassan, M.D.
07:00am, Monday, 13'th Jul 2026
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives Globally renowned retina specialist an
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could
04:44am, Monday, 29'th Jun 2026
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 16'th Jun 2026
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:12pm, Tuesday, 09'th Jun 2026
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
12:05pm, Tuesday, 26'th May 2026
Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 19'th May 2026
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 18'th May 2026
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
– LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four pre
EyePoint: DURAVYU's Durability Could Drive Significant Upside
01:58am, Thursday, 14'th May 2026
EyePoint is rated a clear BUY, with central-case DCF modeling indicating roughly 2x upside from current levels. DURAVYU, EYPT's lead candidate for wet AMD and DME, has demonstrated a compelling durabi
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
05:51pm, Wednesday, 06'th May 2026
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
09:25am, Wednesday, 06'th May 2026
EyePoint (EYPT) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.65 per share a year ago.
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 06'th May 2026
WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with se
